Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/15/2023* 16:30 EST Earnings Call Q4 2022 -- -- --
02/15/2023* -- Results Q4 2022 -- -0.36 --
11/07/2022 -- Results Q3 2022 -0.32 -0.33 3.03%
11/07/2022 17:00 EST Earnings Call Q3 2022 -- -- --
08/03/2022 17:00 EST Earnings Call Q2 2022 -- -- --
08/03/2022 -- Results Q2 2022 -0.34 -0.34 0.00%
05/04/2022 17:00 EST Earnings Call Q1 2022 -- -- --
05/04/2022 -- Results Q1 2022 -0.37 -0.32 -16.54%
*Estimated Date/Time

Earnings

Next Report Date 02/15/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/07/2022
Beat/Miss Upgrade
Return Since 20.07%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe.
URL https://www.pacb.com
Investor Relations URL https://investor.pacificbiosciences.com
HQ State/Province California
Sector Healthcare
Industry Medical Devices
Equity Style Small Cap/Growth
Next Earnings Release Feb. 15, 2023 (est.)
Last Earnings Release Nov. 07, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
67.47%
-71.06%
-30.53%
180.3%
-30.54%
404.7%
-21.13%
-50.59%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-14.29%
--
--
--
-43.56%
-39.92%
938.9%
-3.98%
-62.82%
-29.63%
-52.07%
-43.76%
-71.37%
-38.63%
70.63%
-53.49%
-79.00%
--
--
-0.37%
-2.63%
-64.63%
-4.83%
206.3%
-56.55%
15.38%
1.56%
-35.67%
-38.44%
161.9%
-17.93%
-19.28%
-26.43%
As of November 25, 2022.

Profile

Edit
Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe.
URL https://www.pacb.com
Investor Relations URL https://investor.pacificbiosciences.com
HQ State/Province California
Sector Healthcare
Industry Medical Devices
Equity Style Small Cap/Growth
Next Earnings Release Feb. 15, 2023 (est.)
Last Earnings Release Nov. 07, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
CARKCX 887.00 USD 8.87%
CGARBX 649.00 USD 6.49%
F00001CYG9 645.00 USD 6.45%
ARKG 126.46M USD 5.56%
JSMVX 42.71M USD 4.68%
GNOM 7.136M USD 3.52%
EDOC 4.837M USD 3.33%
NXTE 1.274M USD 2.31%
ARKK 156.89M USD 2.16%
EARK.NO 1.239M USD 1.59%
ADNRX 3.234M USD 1.29%
KRXCX 53040.00 USD 0.29%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter PACB Tweets